Trial Profile

A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort Turbuhaler) 320/9 µg one inhalation twice daily on top of tiotropium (Spiriva) 18 µg one inhalation once daily compared with tiotropium 18 µg one inhalation once daily, in patients with severe chronic obstructive pulmonary disease (COPD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2012 Official title amended as reported by European Clinical Trials Database.
05 Nov 2009 Symptom exacerbation results were reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
05 Nov 2009 Results were reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com